The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ

Science Signaling

Volumn 10, Issue 508, 2017, Pages

  Edwards, Deanna N ^a   Ngwa, Verra M ^a   Wang, Shan ^a   Shiuan, Eileen ^a   Brantley Sieders, Dana M ^a   Kim, Laura C ^a   Reynolds, Albert B ^a   Chen, Jin ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; GLS PROTEIN; GLUTAMINE; PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROCK PROTEIN; SLC1A5 PROTEIN; TAZ PROTEIN; TEAD4 PROTEIN; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; DNA BINDING PROTEIN; EPHA2 RECEPTOR, HUMAN; EPHRIN A2; GLS1 PROTEIN, HUMAN; GLUTAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; MUSCLE PROTEIN; PHOSPHOPROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SLC1A5 PROTEIN, HUMAN; TEAD4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; WWTR1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; MCF-10A-NEOT CELL LINE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY DNA SEQUENCE; ANIMAL; BREAST TUMOR; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; TUMOR CELL CULTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID TRANSPORT SYSTEM ASC; ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EPHRIN-A2; FEMALE; GLUTAMINASE; GLUTAMINE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MINOR HISTOCOMPATIBILITY ANTIGENS; MUSCLE PROTEINS; PHOSPHOPROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 85037636870     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aan4667     Document Type: Article

References (95)

1. M. A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
2. V. M. Youngblood, L. C. Kim, D. N. Edwards, Y. Hwang, P. R. Santapuram, S. M. Stirdivant, P. Lu, F. Ye, D. M. Brantley-Sieders, J. Chen, The ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer. Cancer Res. 76, 1825-1836 (2016).
3. E. B. Pasquale, Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165-180 (2010).
4. D. M. Brantley-Sieders, A. Jiang, K. Sarma, A. Badu-Nkansah, D. L. Walter, Y. Shyr, J. Chen, Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLOS ONE 6, e24426 (2011).
5. D. M. Brantley-Sieders, G. Zhuang, D. Hicks, W. B. Fang, Y. Hwang, J. M. M. Cates, K. Coffman, D. Jackson, E. Bruckheimer, R. S. Muraoka-Cook, J. Chen, The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 118, 64-78 (2008).
6. H. Miao, D.-Q. Li, A. Mukherjee, H. Guo, A. Petty, J. Cutter, J. P. Basilion, J. Sedor, J. Wu, D. Danielpour, A. E. Sloan, M. L. Cohen, B. Wang, EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009).
7. D. Vaught, D. M. Brantley-Sieders, J. Chen, Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression. Breast Cancer Res. 10, 217 (2008).
8. J. Chen, Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv. Cancer Res. 114, 1-20 (2012).
9. W. B. Fang, R. C. Ireton, G. Zhuang, T. Takahashi, A. Reynolds, J. Chen, Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J. Cell Sci. 121, 358-368 (2008).
10. G. Zhuang, D. M. Brantley-Sieders, D. Vaught, J. Yu, L. Xie, S. Wells, D. Jackson, R. Muraoka-Cook, C. Arteaga, J. Chen, Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70, 299-308 (2010).
11. M. Macrae, R. M. Neve, P. Rodriguez-Viciana, C. Haqq, J. Yeh, C. Chen, J. W. Gray, F. McCormick, A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8, 111-118 (2005).
12. M. Overholtzer, J. Zhang, G. A. Smolen, B. Muir, W. Li, D. C. Sgroi, C.-X. Deng, J. S. Brugge, D. A. Haber, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U.S.A. 103, 12405-12410 (2006).
13. X. Wang, L. Su, Q. Ou, Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur. J. Cancer 48, 1227-1234 (2012).
14. D. Zhao, X. Zhi, Z. Zhou, C. Chen, TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 33, 59-67 (2012).
15. S. W. Chan, C. J. Lim, K. Guo, C. P. Ng, I. Lee, W. Hunziker, Q. Zeng, W. Hong, A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68, 2592-2598 (2008).
16. F. Zanconato, M. Forcato, G. Battilana, L. Azzolin, E. Quaranta, B. Bodega, A. Rosato, S. Bicciato, M. Cordenonsi, S. Piccolo, Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17, 1218-1227 (2015).
17. H. Zhang, C.-Y. Liu, Z.-Y. Zha, B. Zhao, J. Yao, S. Zhao, Y. Xiong, Q.-Y. Lei, K.-L. Guan, TEAD transcription factors mediate the function of TAZ in cell growth and epithelialmesenchymal transition. J. Biol. Chem. 284, 13355-13362 (2009).
18. A. Vassilev, K. J. Kaneko, H. Shu, Y. Zhao, M. L. DePamphilis, TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 15, 1229-1241 (2001).
19. B. Zhao, X. Ye, J. Yu, L. Li, W. Li, S. Li, J. Yu, J. D. Lin, C.-Y. Wang, A. M. Chinnaiyan, Z.-C. Lai, K.-L. Guan, TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22, 1962-1971 (2008).
20. S.W. Chan, C. J. Lim, L. S. Loo, Y. F. Chong, C. Huang, W. Hong, TEADsmediate nuclear retention of TAZ to promote oncogenic transformation. J. Biol. Chem. 284, 14347-14358 (2009).
21. F. Kanai, P. A. Marignani, D. Sarbassova, R. Yagi, R. A. Hall, M. Donowitz, A. Hisaminato, T. Fujiwara, Y. Ito, L. C. Cantley, M. B. Yaffe, TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19, 6778-6791 (2000).
22. J. Dong, G. Feldmann, J. Huang, S. Wu, N. Zhang, S. A. Comerford, M. F. Gayyed, R. A. Anders, A. Maitra, D. Pan, Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133 (2007).
23. X. Hong, H. T. Nguyen, Q. Chen, R. Zhang, Z. Hagman, P. M. Voorhoeve, S. M. Cohen, Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J. 33, 2447-2457 (2014).
24. B. Zhao, X. Wei, W. Li, R. S. Udan, Q. Yang, J. Kim, J. Xie, T. Ikenoue, J. Yu, L. Li, P. Zheng, K. Ye, A. Chinnaiyan, G. Halder, Z.-C. Lai, K.-L. Guan, Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007).
25. B. Zhao, L. Li, K. Tumaneng, C.-Y. Wang, K.-L. Guan, A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFb-TRCP. Genes Dev. 24, 72-85 (2010).
26. C.-Y. Liu, Z.-Y. Zha, X. Zhou, H. Zhang, W. Huang, D. Zhao, T. Li, S. W. Chan, C. J. Lim, W. Hong, S. Zhao, Y. Xiong, Q.-Y. Lei, K.-L. Guan, The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFb-TrCP E3 ligase. J. Biol. Chem. 285, 37159-37169 (2010).
27. K. F. Harvey, X. Zhang, D. M. Thomas, The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
28. R. Johnson, G. Halder, The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 13, 63-79 (2014).
29. M. Cordenonsi, F. Zanconato, L. Azzolin, M. Forcato, A. Rosato, C. Frasson, M. Inui, M. Montagner, A. R. Parenti, A. Poletti, M. G. Daidone, S. Dupont, G. Basso, S. Bicciato, S. Piccolo, The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772 (2011).
30. R. Fan, N.-G. Kim, B. M. Gumbiner, Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc. Natl. Acad. Sci. U.S.A. 110, 2569-2574 (2013).
31. D. R. Wise, C. B. Thompson, Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 35, 427-433 (2010).
32. C. T. Hensley, A. T. Wasti, R. J. DeBerardinis, Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678-3684 (2013).
33. N. E. Simpson, V. P. Tryndyak, F. A. Beland, I. P. Pogribny, An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res. Treat. 133, 959-968 (2012).
34. V. M. Asiago, L. Z. Alvarado, N. Shanaiah, G. A. N. Gowda, K. Owusu-Sarfo, R. A. Ballas, D. Raftery, Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 70, 8309-8318 2010).
35. Y. Kanai, M. A. Hediger, The glutamate/neutral amino acid transporter family SLC1: Molecular, physiological and pharmacological aspects. Pflugers Arch. 447, 469-479 (2004).
36. R. Kekuda, P. D. Prasad, Y.-J. Fei, V. Torres-Zamorano, S. Sinha, T. L. Yang-Feng, F. H. Leibach, V. Ganapathy, Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line. J. Biol. Chem. 271, 18657-18661 (1996).
37. J. C. Aledo, P. M. Gómez-Fabre, L. Olalla, J. Marquez, Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm. Genome 11, 1107-1110 (2000).
38. S. Kim, D. H. Kim, W.-H. Jung, J. S. Koo, Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr. Relat. Cancer 20, 339-348 (2013).
39. S. Qie, C. Chu, W. Li, C. Wang, N. Sang, ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J. Cell. Biochem. 115, 498-509 (2014).
40. J.-B. Wang, J. W. Erickson, R. Fuji, S. Ramachandran, P. Gao, R. Dinavahi, K. F. Wilson, A. L. B. Ambrosio, S. M. G. Dias, C. V. Dang, R. A. Cerione, Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
41. S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti, M. Cordenonsi, F. Zanconato, J. Le Digabel, M. Forcato, S. Bicciato, N. Elvassore, S. Piccolo, Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
42. M. Z. Xu, S. W. Chan, A. M. Liu, K. F. Wong, S. T. Fan, J. Chen, R. T. Poon, L. Zender, S. W. Lowe, W. Hong, J. M. Luk, AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30, 1229-1240 (2011).
43. D. Lai, K. C. Ho, Y. Hao, X. Yang, Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71, 2728-2738 (2011).
44. W. Lehmann, D. Mossmann, J. Kleemann, K. Mock, C. Meisinger, T. Brummer, R. Herr, S. Brabletz, M. P. Stemmler, T. Brabletz, ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498 (2016).
45. D. M. Brantley, N. Cheng, E. J. Thompson, Q. Lin, R. A. Brekken, P. E. Thorpe, R. S. Muraoka, D. P. Cerretti, A. Pozzi, D. Jackson, C. Lin, J. Chen, Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011-7026 (2002).
46. C. Gundry, S. Marco, E. Rainero, B. Miller, E. Dornier, L. Mitchell, P. T. Caswell, A. D. Campbell, A. Hogeweg, O. J. Sansom, J. P. Morton, J. C. Norman, Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion. Nat. Commun. 8, 14646 (2017).
47. K. Miura, Y. Wakayama, M. Tanino, Y. Orba, H. Sawa, M. Hatakeyama, S. Tanaka, H. Sabe, N. Mochizuki, Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 32, 5292-5301 (2013).
48. M. Parri, M. L. Taddei, F. Bianchini, L. Calorini, P. Chiarugi, EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 69, 2072-2081 (2009).
49. M. Amano, M. Ito, K. Kimura, Y. Fukata, K. Chihara, T. Nakano, Y. Matsuura, K. Kaibuchi, Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271, 20246-20249 (1996).
50. C. Herraiz, F. Calvo, P. Pandya, G. Cantelli, I. Rodriguez-Hernandez, J. L. Orgaz, N. Kang, T. Chu, E. Sahai, V. Sanz-Moreno, Reactivation of p53 by a cytoskeletal sensor to control the balance between DNA damage and tumor dissemination. J. Natl. Cancer Inst. 108, djv289 (2016).
51. M. Willenborg, U. Panten, I. Rustenbeck, Triggering and amplification of insulin secretion by dimethyl a-ketoglutarate, a membrane permeable a-ketoglutarate analogue. Eur. J. Pharmacol. 607, 41-46 (2009).
52. K. M. Elgadi, R. A. Meguid, M. Qian, W. W. Souba, S. F. Abcouwer, Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genomics 1, 51-62 (1999).
53. A. Cassago, A. P. S. Ferreira, I. M. Ferreira, C. Fornezari, E. R. M. Gomes, K. S. Greene, H. M. Pereira, R. C. Garratt, S. M. G. Dias, A. L. B. Ambrosio, Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl. Acad. Sci. U.S.A. 109, 1092-1097 (2012).
54. M. I. Gross, S. D. Demo, J. B. Dennison, L. Chen, T. Chernov-Rogan, B. Goyal, J. R. Janes, G. J. Laidig, E. R. Lewis, J. Li, A. L. Mackinnon, F. Parlati, M. L. M. Rodriguez, P. J. Shwonek, E. B. Sjogren, T. F. Stanton, T. Wang, J. Yang, F. Zhao, M. K. Bennett, Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890-901 (2014).
55. P. Gao, I. Tchernyshyov, T.-C. Chang, Y.-S. Lee, K. Kita, T. Ochi, K. I. Zeller, A. M. De Marzo, J. E. Van Eyk, J. T. Mendell, C. V. Dang, c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
56. D. R. Wise, R. J. DeBerardinis, A. Mancuso, N. Sayed, X.-Y. Zhang, H. K. Pfeiffer, I. Nissim, E. Daikhin, M. Yudkoff, S. B. McMahon, C. B. Thompson, Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A. 105, 18782-18787 (2008).
57. ENCODE Project Consortium, An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
58. A. Barski, S. Cuddapah, K. Cui, T.-Y. Roh, D. E. Schones, Z. Wang, G. Wei, I. Chepelev, K. Zhao, High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007).
59. Z. Wang, C. Zang, J. A. Rosenfeld, D. E. Schones, A. Barski, S. Cuddapah, K. Cui, T.-Y. Roh, W. Peng, M. Q. Zhang, K. Zhao, Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 40, 897-903 (2008).
60. C. Stein, A. F. Bardet, G. Roma, S. Bergling, I. Clay, A. Ruchti, C. Agarinis, T. Schmelzle, T. Bouwmeester, D. Schübeler, A. Bauer, YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers. PLOS Genet. 11, e1005465 (2015).
61. A. Anbanandam, D. C. Albarado, C. T. Nguyen, G. Halder, X. Gao, S. Veeraraghavan, Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. Proc. Natl. Acad. Sci. U.S.A. 103, 17225-17230 (2006).
62. A. J. Minn, G. P. Gupta, P. M. Siegel, P. D. Bos, W. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald, J. Massague, Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
63. B. Györffy, A. Lanczky, A. C. Eklund, C. Denkert, J. Budczies, Q. Li, Z. Szallasi, An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).
64. W. B. Fang, D. M. Brantley-Sieders, Y. Hwang, A.-J. L. Ham, J. Chen, Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 283, 16017-16026 (2008).
65. K. Harada, M. Negishi, H. Katoh, HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture. J. Cell Sci. 128, 1912-1921 (2015).
66. K. Kullander, R. Klein, Mechanisms and functions of eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3, 475-486 (2002).
67. K. D. Kikawa, D. R. Vidale, R. L. Van Etten, M. S. Kinch, Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 277, 39274-39279 (2002).
68. J.-S. Mo, F.-X. Yu, R. Gong, J. H. Brown, K.-L. Guan, Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 26, 2138-2143 (2012).
69. F.-X. Yu, B. Zhao, N. Panupinthu, J. L. Jewell, I. Lian, L. H. Wang, J. Zhao, H. Yuan, K. Tumaneng, H. Li, X.-D. Fu, G. B. Mills, K.-L. Guan, Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791 (2012).
70. M. Aragona, T. Panciera, A. Manfrin, S. Giulitti, F. Michielin, N. Elvassore, S. Dupont, S. Piccolo, A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154, 1047-1059 (2013).
71. B. Zhao, L. Li, Q. Lu, L. H. Wang, C.-Y. Liu, Q. Lei, K.-L. Guan, Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25, 51-63 (2011).
72. K. Wang, F. Cao, W. Fang, Y. Hu, Y. Chen, H. Ding, G. Yu, Activation of SNAT1/SLC38A1 in human breast cancer: Correlation with p-Akt overexpression. BMC Cancer 13, 343 (2013).
73. Z. Liang, H. T. Cho, L. Williams, A. Zhu, K. Liang, K. Huang, H. Wu, C. Jiang, S. Hong, R. Crowe, M. M. Goodman, H. Shim, Potential biomarker of L-type amino acid transporter 1 in breast cancer progression. Nucl. Med. Mol. Imaging 45, 93-102 (2011).
74. M. van Geldermalsen, Q. Wang, R. Nagarajah, A. D. Marshall, A. Thoeng, D. Gao, W. Ritchie, Y. Feng, C. G. Bailey, N. Deng, K. Harvey, J. M. Beith, C. I. Selinger, S. A. O'Toole, J. E. J. Rasko, J. Holst, ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35, 3201-3208 (2016).
75. Y. Xiang, Z. E. Stine, J. Xia, Y. Lu, R. S. O'Connor, B. J. Altman, A. L. Hsieh, A. M. Gouw, A. G. Thomas, P. Gao, L. Sun, L. Song, B. Yan, B. S. Slusher, J. Zhuo, L. L. Ooi, C. G. L. Lee, A. Mancuso, A. S. McCallion, A. Le, M. C. Milone, S. Rayport, D. W. Felsher, C. V. Dang, Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293-2306 (2015).
76. F. Huang, Q. Zhang, H. Ma, Q. Lv, T. Zhang, Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int. J. Clin. Exp. Pathol. 7, 1093-1100 (2014).
77. B. J. Altman, Z. E. Stine, C. V. Dang, From Krebs to clinic: Glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619-634 (2016).
78. L. Xiang, G. Xie, C. Liu, J. Zhou, J. Chen, S. Yu, J. Li, X. Pang, H. Shi, H. Liang, Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim. Biophys. Acta 1833, 2996-3005 (2013).
79. J. Zhang, C. Wang, M. Chen, J. Cao, Y. Zhong, L. Chen, H. M. Shen, D. Xia, Epigenetic silencing of glutaminase 2 in human liver and colon cancers. BMC Cancer 13, 601 (2013).
80. J. Liu, C. Zhang, M. Lin, W. Zhu, Y. Liang, X. Hong, Y. Zhao, K. H. Young, W. Hu, Z. Feng, Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 5, 2635-2647 (2014).
81. C. Zhang, J. Liu, Y. Zhao, X. Yue, Y. Zhu, X. Wang, H. Wu, F. Blanco, S. Li, G. Bhanot, B. G. Haffty, W. Hu, Z. Feng, Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. eLife 5, e10727 (2016).
82. T. Bertero, W. M. Oldham, K. A. Cottrill, S. Pisano, R. R. Vanderpool, Q. Yu, J. Zhao, Y. Tai, Y. Tang, Y. Y. Zhang, S. Rehman, M. Sugahara, Z. Qi, J. Gorcsan III, S. O. Vargas, R. Saggar, R. Saggar, W. D. Wallace, D. J. Ross, K. J. Haley, A. B. Waxman, V. N. Parikh, T. De Marco, P. Y. Hsue, A. Morris, M. A. Simon, K. A. Norris, C. Gaggioli, J. Loscalzo, J. Fessel, S. Y. Chan, Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J. Clin. Invest. 126, 3313-3335 (2016).
83. A. G. Cox, K. L. Hwang, K. K. Brown, K. J. Evason, S. Beltz, A. Tsomides, K. O'Connor, G. G. Galli, D. Yimlamai, S. Chhangawala, M. Yuan, E. C. Lien, J. Wucherpfennig, S. Nissim, A. Minami, D. E. Cohen, F. D. Camargo, J. M. Asara, Y. Houvras, D. Y. R. Stainier, W. Goessling, Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat. Cell Biol. 18, 886-896 (2016).
84. Y. Y. Park, B. H. Sohn, R. L. Johnson, M.-H. Kang, S. B. Kim, J.-J. Shim, L. S. Mangala, J. H. Kim, J. E. Yoo, C. Rodriguez-Aguayo, S. Pradeep, J. E. Hwang, H.-J. Jang, H.-S. Lee, R. Rupaimoole, G. Lopez-Berestein, W. Jeong, I. S. Park, Y. N. Park, A. K. Sood, G. B. Mills, J.-S. Lee, Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology 63, 159-172 (2016).
85. K. Garber, Cancer anabolic metabolism inhibitors move into clinic. Nat. Biotechnol. 34, 794-795 (2016).
86. B. von Eyss, L. A. Jaenicke, R. M. Kortlever, N. Royla, K. E. Wiese, S. Letschert, L. A. McDuffus, M. Sauer, A. Rosenwald, G. I. Evan, S. Kempa, M. Eilers, A MYC-driven change in mitochondrial dynamics limits YAP/TAZ function in mammary epithelial cells and breast cancer. Cancer Cell 28, 743-757 (2015).
87. X. Liu, H. Li, M. Rajurkar, Q. Li, J. L. Cotton, J. Ou, L. J. Zhu, H. L. Goel, A. M. Mercurio, J.-S. Park, R. J. Davis, J. Mao, Tead and AP1 coordinate transcription and motility. Cell Rep. 14, 1169-1180 (2016).
88. A. Sawada, H. Kiyonari, K. Ukita, N. Nishioka, Y. Imuta, H. Sasaki, Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol. Cell. Biol. 28, 3177-3189 (2008).
89. M. Rao, W. Song, A. Jiang, Y. Shyr, S. Lev, D. Greenstein, D. Brantley-Sieders, J. Chen, VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. PLOS ONE 7, e46281 (2012).
90. R. S. Muraoka, Y. Koh, L. R. Roebuck, M. E. Sanders, D. Brantley-Sieders, A. E. Gorska, H. L. Moses, C. L. Arteaga, Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor b1. Mol. Cell. Biol. 23, 8691-8703 (2003).
91. J. Debnath, S. K. Muthuswamy, J. S. Brugge, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268 (2003).
92. Y. Ueda, S. Wang, N. Dumont, J. Y. Yi, Y. Koh, C. L. Arteaga, Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor b-induced cell motility. J. Biol. Chem. 279, 24505-24513 (2004).
93. D. M. Bryant, A. Datta, A. E. Rodríguez-Fraticelli, J. Peränen, F. Martín-Belmonte, K. E. Mostov, A molecular network for de novo generation of the apical surface and lumen. Nat. Cell Biol. 12, 1035-1045 (2010).
94. D. Schmidt, M. D. Wilson, C. Spyrou, G. D. Brown, J. Hadfield, D. T. Odom, ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).
95. D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, A. M. Chinnaiyan, ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 (2004).